We applied monoclonal antibodies against RET and cytokeratin 19 
Neoplasms of the thyroid frequently present diagnostic challenges. Although the question often focuses on whether criteria are sufficient to warrant a diagnosis of encapsulated follicular carcinoma (FC) as opposed to follicular adenoma (FA), the distinction of follicular lesions from the follicular variant of papillary carcinoma (PC) can be equally problematic. The separation of follicular variants of PC from other follicular lesions continues to rely solely on morphologic criteria. Differential cytokeratin profiles as detected by immunohistochemical analysis have been proposed as adjuvant diagnostic tests. [1] [2] [3] [4] [5] Specifically, cytokeratin 19 (CK19) has become an accepted marker to help distinguish PC from FA. [1] [2] [3] [4] [5] [6] Because no single marker is completely sensitive or specific, additional agents to facilitate the distinction of the follicular variant of PC from follicular mimics continue to be sought.
The sporadic form of PC of the thyroid is associated with an oncogenic form of RET, a tyrosine kinase involved in signal transduction. The RET gene is activated by rearrangement with one of several different genes, resulting in the fusion of the RET tyrosine-kinase domain to a 5' terminal region of one of the heterologous genes. This creates a RET/PTC product with constitutive kinase activity. 7, 8 The development of the RET/PTC oncogene is believed to be oncogenic for PC. Transgenic mice carrying the RET/PTC oncogene develop thyroid tumors with a papillary pattern and classic nuclear features identical to papillary tumors in humans. 9, 10 Interestingly, not all transgenic mice developed thyroid tumors, implying that the expression of the oncoprotein is necessary but not sufficient for tumorigenesis. Conversely, wide differences in the prevalence of RET/PTC rearrangements in human PC have been reported, ranging from 5% to 67%. [11] [12] [13] [14] [15] [16] [17] [18] Clearly tumorigenesis involves multiple "hits," and other genetic lesions are likely involved in the development of some cases of PC.
The diagnostic potential of the RET oncogene for pathologists lies in its reported specificity for PCs. 14 Studies using in situ hybridization have detected RET messenger RNA in 43% of PCs and its absence in FCs, FAs, nodular hyperplasias, and normal thyroid. 14, 18 Close correlation between reverse transcriptase-polymerase chain reaction (RT-PCR) detection of RET/PTC and immunohistochemical detection of ret protein product has been observed. 1, 9 It follows that immunohistochemical detection of the RET protein may serve as a useful adjunct for the diagnosis of PC, particularly in variant forms that are challenging by routine light microscopy. By using immunohistochemical analysis and RT-PCR, we assessed a variety of follicular lesions for the presence of ret protein product. Criteria for inclusion of a tumor as an FVPC followed those outlined in the Armed Forces Institute of Pathology Tumors of the Thyroid Gland. 19 These tumors are composed exclusively or almost exclusively of a follicular pattern of growth, lack a well-developed capsule, often show extensive fibrous septa, and may contain scattered psammoma bodies. 19, 20 The follicles may show irregularities of their lining epithelium, with formations of folds or intraluminal protrusions, features that were noted in 2 of 12 cases of FVPC in the present study. All cases included as FVPC showed the typical nuclear features of conventional PC, although in 3 cases, the features were focal.
Materials and Methods

Tumor Selection
We included 2 unusual variants of PC in the study. One case showed a uniform papillary architecture with fibrovascular cores lined by ovoid cells containing granular, eosinophilic cytoplasm. The majority of the nuclei showed irregular outlines and grooves, and inclusions were easily identified ❚Image 1❚. A "Warthin-like" stroma was not present. This case has been referred to as "the oncocytic variant" of PC 21, 22 or the Hürthle cell variant of PC, 23 and, for the purposes of the present study, was classified as the latter (HPC). The second infrequently encountered PC variant showed a follicular proliferation of cells embedded in an unusual stroma, characterized by dense sclerosis admixed with loosely textured spindle cells and scattered lymphoid cells ❚Image 2❚. 24, 25 The nonneoplastic adjacent thyroid lacked an inflammatory component and Hashimoto thyroiditis. These features are consistent with those described as PC with sclerotic and nodular fasciitis-like stroma (SPC). Neoplasms classified as FA were completely or partially encapsulated. The chromatin was fine or mildly coarse but lacked the optical clearing found in PC. Nuclear outlines were smooth, and inclusions were absent. An occasional nuclear groove was allowed in this category. Follicular carcinomas showed obvious local invasion into adjacent structures and varied from an insular pattern to solid nodules of back-to-back follicles. The distinction between adenoma and carcinoma among these lesions was unambiguous, as all cases of FC showed unequivocal vascular and capsular invasion. Three cases of FC with aggressive local features (eg, widespread extrathyroidal extension) were located in our files, but all showed intermingled anaplastic morphologic features. We did not include them in this study, as such cases would not be confused with other follicular lesions.
Hürthle cell lesions were uniformly composed of cells containing granular, brightly eosinophilic cytoplasm. The nuclei in both HA and HC showed finely dispersed chromatin with a distinct nucleolus. Well-circumscribed lesions were designated as adenomas (HA), and those with extension beyond the capsule or with large vessel invasion were categorized as carcinomas (HC). In each case designated HC, extension beyond the capsule was widespread, and separation from HA was straightforward.
Immunohistochemical Analysis
Consecutive 4-µm sections for immunohistochemical analysis were deparaffinized and placed in 1.5% hydrogen peroxide/methanol for 10 minutes. For RET immunostaining, epitope retrieval was performed by transferring the slides to a 0.01-mol/L concentration of sodium citrate buffer (pH 6.0) and microwaving for 20 minutes.
Consecutive sections were incubated with monoclonal RET antibody (3F8 clone; 1:100 dilution; Novocastra, Burlingame, CA) or monoclonal CK19 antibody (b170 clone; 1:100 dilution, Novocastra) using the avidin-biotin peroxidase complex amplification and detection system on an automated immunostainer (Ventana Medical Systems, Tucson, AZ). An endogenous biotin blocking step was included. Appropriate positive and negative controls were included with each immunostaining procedure. Sections then were incubated with biotinylated antimouse immunoglobulin, streptavidin-horseradish peroxidase, with a chromogenic substrate, diaminobenzidine. Hematoxylin counterstaining was performed.
Repeated immunohistochemical staining using an amplification technique for RET was performed on the cases of PC and FVPC that lacked RET immunostaining (PC cases 10, 13, 15, and 16; FVPC cases 3, 8-10, and 12). The identical steps and controls were performed as outlined in the preceding text, with the addition of the use of a Ventana Amplification Kit. The use of this kit involves rabbit antimouse IgG heavy and light chains (amplifier A) and mouse antirabbit.
Interpretation
Immunoreactivity was evaluated using a consensus of 3 of us (L.A.C., S.E.M., and C.A.M.) with agreement in all cases. The immunolabeling pattern for CK19 and RET staining fell into 1 of 3 categories: strongly positive, weakly positive, or negative. Neoplasms scored as strongly positive showed uniform, intense cytoplasmic labeling with accentuation of the cytoplasmic membrane. Neoplasms scored as weakly positive showed faint cytoplasmic staining with interspersed negative cells. Tumors were considered negative if staining was completely absent or present in only 1 or 2 scattered cells. The percentage of tumor cells staining was interpreted as follows: diffuse, more than 75%; patchy, 16% to 75%; rare, 1% to 15%.
Reverse Transcriptase-Polymerase Chain Reaction
Formalin-fixed, paraffin-embedded sections were stained with methylene blue and eosin, and manual dissection was performed under microscopic visualization to obtain tumor samples of more than 95% purity. Samples were placed in guanidine isothiocyanate buffer, and treated with Proteinase K followed by organic extraction and alcohol precipitation. Standard first-strand synthesis using SuperScript II (Life Technologies, Bethesda, MD) with random hexamers was performed in 50-µL reaction volumes. The presence or absence of RET expression was evaluated by RT-PCR performed on 5 µL of the complementary DNA (cDNA) template using the primers cRET-1F CTTGTCCCGAGAT-GTTTATG and cRET-1R TGGTGTAGATATGAT-CAAAAAG, which amplify a 107-base-pair (bp) fragment corresponding to residues 2631 to 2737 of the RET cDNA sequence. These primers flank the intron-exon boundary between exons 14 and 15 in the tyrosine kinase domain, allowing the discrimination between RET cDNA and the genomic sequence, which produces an 1,849-bp product. The presence of amplifiable cDNA in the samples was verified by parallel RT-PCR for beta 2 -microglobulin using primers that produce amplicons of 106 and 722 bp from cDNA and genomic DNA, respectively (F-ATTCACCCCCACT-GAAAAAG; R-CCATGATGCTGCTTACATG). Ten microliters of each RT-PCR reaction were subjected to agarose gel electrophoresis and analyzed on an AlphaImager 2000 gel documentation system (Alpha Innotech, San Leandro, CA). 
RET
The results of immunostaining for RET are summarized in Tables 1 and 2 
Reverse Transcriptase-Polymerase Chain Reaction
Given that the staining for RET in Hürthle cell lesions appeared qualitatively more homogeneous and less granular than the staining in PC, we questioned whether the homogeneous immunopositivity represented true RET protein or an artifact of nonspecific staining. The Hürthle cell lesions therefore were selected for RT-PCR to evaluate for the presence of the RET transcript. Six Hürthle cell lesions (3 HAs and 3 HCs) were selected for RT-PCR to evaluate for the presence of the RET protein. The results showed that the RET transcript was present in all Hürthle cell neoplasms (adenomas and carcinomas) ❚Image 9❚.
Discussion
Activation of the RET/PTC proto-oncogene has been reported to be a specific genetic event linked to the development of PC of the thyroid. 9, 14, 18, 26 The rearranged protooncogene, RET/PTC, results from the juxtaposition of the 3' tyrosine kinase domain of the RET gene with the 5' domain of ubiquitously expressed genes, resulting in constitutive activation of the RET tyrosine kinase. The majority of studies, with notable exceptions, have failed to detect RET activation in thyroid tumors other than the papillary types. [26] [27] [28] Our findings suggest that the pattern and intensity of RET staining should be interpreted with caution in the evaluation of an individual follicular thyroid lesion. One could argue that strong, diffuse granular staining for RET in a follicular lesion favors FVPC, since this pattern was ❚Image 4❚ Uniformly strong immunostaining in a typical papillary carcinoma (cytokeratin 19 immunostain, ×4).
❚Image 5❚ Follicular variant of papillary carcinoma stains strongly in a pattern and intensity similar to that for classic papillary carcinoma (cytokeratin 19, ×20).
observed only in a subset of PCs and FVPCs. Our ability to discriminate weak from strong staining developed only after scrutinizing a series of cases and carefully comparing the staining intensity. Thus, we would anticipate unacceptably high interobserver and intraobserver variability among pathologists who are faced with interpreting a single RET immunostain without the benefit of careful study of a substantial number of RET-immunostained lesions. The more problematic issue is the lack of RET staining in cases of clear-cut PC.
To confirm the lack of RET protein detection by immunohistochemical means, PCs that lacked RET staining underwent repeated RET immunostaining using an immunoamplification procedure and, again, did not stain. This indicates that negative RET staining within an individual follicular lesion should not be regarded as exclusionary of PC.
In the present study, another unexpected finding was focal and weak RET immunostaining in 2 FAs. We reviewed the light microscopic findings in these 2 cases of FA and did not detect features of PC. In addition, the 2 RET-positive cases of FA demonstrated weak and patchy CK19 staining, unlike the strong, diffuse pattern of CK19 evident in FVPCs. Although positive RET staining in 2 FAs seemingly poses a specificity problem, staining in the FAs was limited to only a minor proportion of the lesion (<20%) and lacked the intensity seen Hürthle cells lesions of the thyroid also have been found to harbor the RET/PTC rearrangement, in some cases leading to reclassification as FVPC with Hürthle cell features. 23 All of the Hürthle cell lesions in our study, which included 4 HAs, 3 HCs, and 1 HPC showed diffuse, finely granular to homogeneous cytoplasmic RET staining. This appeared qualitatively different from the granular to globular staining pattern in PC. Given that Hürthle cells contain large numbers of mitochondria with a high content of oxidative enzymes, the possibility that the immunostain was nonspecifically trapped within the cytoplasm was considered. However, results of our RT-PCR showed that the RNA transcript for the RET kinase domain was present in these lesions, suggesting that the immunohistologic detection of RET in our Hürthle lesions is real. Since our RT-PCR assay was not designed to detect gene rearrangement, it is not known whether the result was due to induced expression of wildtype RET protein or represents activation by RET/PTC fusion. In a study by Cheung et al, 23 a subset of Hürthle cell lesions did not show RET/PTC rearrangement. Lesions that exhibited RET/PTC transcripts showed clear architectural and cytologic features of papillary thyroid carcinoma, in addition to the Hürthle cell changes of the cytoplasm. The Hürthle cell lesions in our study did not show papillary architectural features, with the exception of the case designated as HPC.
Our results corroborate the usefulness of CK19 reported by others. 5, 6, 29, 30 We illustrated strong, diffuse CK19 expression in the vast majority of PCs, as well as the follicular, Hürthle cell, and sclerosing variants of this tumor. Nonpapillary carcinomas and adenomas showed CK19 staining, but the pattern and intensity were clearly different. Although somewhat more than half of the FAs and FCs were CK19 positive, the staining was patchy and much less intense compared with staining of the PCs. When reviewing Figure  1 , one should keep in mind that it is the overall pattern of uniform strong positivity for CK19 that helps distinguish PC from non-PC. Unlike many stains that can be interpreted as positive or negative, we emphasize that the distribution and intensity of CK19 staining are the most critical aspects of accurate interpretation. One case (FVPC case 8) lacked CK19 staining. Weak or negative staining for FVPC has been reported previously in a minor subset of cases. 1 Review of FVPC case 8 demonstrated a typical FVPC with the expected nuclear features of PC throughout the lesion. In contrast with the CK19 positivity in PCs and all but 1 FVPC, 2 FAs and 3 FCs were negative. Therefore, we conclude that the diagnosis of PC should be highly suspect if there is a complete lack of CK19 staining or if the staining is weak and distribution only patchy. In view of our 1 case of FVPC that failed to stain, if the cytologic findings are overwhelmingly convincing, then the diagnosis should not be altered on the basis of cytokeratin results.
Our results demonstrate a subset of PCs of the usual type, as well as of the follicular variant, that lack RET immunoreactivity. Therefore, lack of RET immunostaining in the diagnostic setting of an individual case is not helpful. However, diffuse and intense RET immunostaining corroborates a diagnosis of PC. Cases showing focal and/or weak RET immunostaining should be interpreted judiciously, as the specificity in such instances is limited. The usefulness of CK19 for identifying PC and its histologic variants is confirmed. Hürthle cell lesions are positive for RET immunostaining, which is related to active transcription of the gene. Further studies are warranted to understand the mechanism and consequence of RET expression in this subset of thyroid neoplasms. 
